Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 4, 2004 - Issue 3
Submit an article Journal homepage
13
Views
1
CrossRef citations to date
0
Altmetric
Drug Evaluation

Oral almotriptan: practical uses in the acute treatment of migraine

Andrew J Dowson The King’s Headache Service, King’s College Hospital, Denmark Hill, London, SE5 9RS, UK. [email protected]
Pages 339-348 | Published online: 10 Jan 2014

References

  • Breslau N, Rasmussen BK. The impact of migraine: epidemiology, risk factors and comorbidities. Neurology56\(Suppl. 1), 4–12 (2001).
  • Goadsby PJ, Lipton RB, Ferarri MD. Migraine — current understanding and treatment. N Engl. I Med. 346, 257–270 (2002).
  • Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study. Headache 41, 646–657 (2001).
  • Ferrari MD. The economic burden of migraine to society. PharmacoEconomics13, 667–676 (1998).
  • Lipton RB, Goadsby PJ, Sawyer JPC et al Migraine: diagnosis and assessment of disability. Rev Contemp. Pharmacother. 11, 63–73 (2000).
  • Dowson AJ, Lipscombe S, Sender J, T, Watson D. New guidelines for the management of migraine in primary care. Curt: /1/ed. Res Opin. 18(7), 414–439 (2002).
  • Dowson AJ, Sender J, Lipscombe S et al. Establishing principles for migraine management in primary care. Int. J. Gun. Pract. 57(6), 493–507 (2003).
  • ••Key recent consensus migrainemanagement guidelines.
  • Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT1viD agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet358, 1668–1675 (2001).
  • •The largest and most comprehensive of the triptan meta-analyses.
  • Fox AW. Comparative tolerability of oral 5-HT1viD agonists. Headache 40, 521–527 (2000).
  • Bou J, Domenech T, Puig J, Heredia A et al Pharmacological characterization of almotriptan: an indolic 5-HT receptor agonist for the treatment of migraine. Eur. Pharmacol 410,33–41 (2000).
  • ••Key pharmacological studywith almotriptan.
  • Bou J, Gras J, Cortijo J, Morcillo EJ, Llenas J, Palacios JM. Vascular effects of the new antimigraine agent almotriptan on human cranial and peripheral arteries. Cephalalgia 21(8), 804–812 (2001).
  • Gras J, Bou J, Llenas J, Fernandez AG, Palacios JM. Functional profile of almotriptan in animal models predictive of antimigraine activity. Eurr. j Pharmacol 410(1), 43–51 (2000).
  • Gras J, Cardelus I, Llenas J, Palacios JM. Cardiovascular safety of almotriptan, a new indolic derivative for the treatment of migraine. Eur.j Pharmacol 410(1), 53–59 (2000).
  • Fleishaker JC, McEnroe JD, Azle NE, Francom SF, Carel BJ. Cardiovascular effects of almotriptan in treated hypertensive patients. Clin. Pharmacol Then 71(3), 169–175 (2002).
  • Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine. A comparative review of pharmacology, pharmacokinetics and efficacy. Drugs60, 1259–1287 (2000).
  • Garcia E, Cabarrocas X, Jansat JM. A clinical trial to determine the lack of food interaction on the bioavailability of almotriptan, a new 5HT1B/ID agonist, in healthy volunteers. I-kadache 38, 376 (1998).
  • Cabarrocas X, Jansat JM, Ferrer P, Luria X. Pharmacokinetics and absorption of oral almotriptan during and outside a migraine attack. Cephalalgia l9, 417 (1999).
  • Jansat JM, Costa J, Salva P, Fernandez FJ, Martinez-Tobed A. Absolute bioavailability, pharmacokinetics and urinary excretion of the novel antimigraine agent almotriptan in healthy male volunteers. J. Gun. Pharmacol 42(12), 1303–1310 (1998).
  • Gras J, Llupia J, Llenas J, Palacios JM. Safety profile of almotriptan, a new antimigraine agent. Effects on central nervous system, renal function and respiratory dynamics. Arzneimittelforschung 51, 726–732 (2001).
  • Salva M, Jansat JM, Martinez-Tobed A, Palacios JM. Identification of the human liver enzymes involved in the metabolism of the antimigraine agent almotriptan. Drug. Metab. Dispos. 31, 404–411 (2003).
  • Cabarrocas X, Fernandez FJ, Popescu G, Jansat JM, Molz K, Ferrer P The pharmacokinetics and tolerability of almotriptan in renal impairment. Headache 39, 346 (1999).
  • Cabarrocas X, Warrington SJ, Jansat JM, Zayas JM, Boyce M, Ferrer P Pharmacokinetics and tolerability of oral almotriptan in the elderly. Cephalalgia 19, 363 (1999).
  • Gras J, Llenas J, Jansat JM, Jauregui J, Cabarrocas X, Palacios JM. Almotriptan, a new antimigraine agent: a review. CNS Drug Rev. 8, 217–234 (1999).
  • Fleishaker JC, Sisson TA, Carel BJ, Azie NE. Pharmacokinetic interaction between verapamil and almotriptan in healthy volunteers. Clin. Pharmacol Therapy67, 498–503 (2000).
  • Fleishaker JC, Ryan KK, Jansat JM et al. Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans. BE J. Clin Pharmacol 51, 437–441 (2001).
  • Fleishaker JC, Ryan KK, Carel BJ, Azle NE. Evaluation of the potential pharmacokinetic interaction between almotriptan and fluoxetine in healthy volunteers.' Gun. Pharmacol 41, 217–223 (2001).
  • Fleishaker JC, Sisson TA, Carel BJ, Azie NE. Lack of pharmacokinetic interaction between the antimigraine compound, almotriptan and propranolol in healthy volunteers. Cephalalgia 2l, 61–65 (2001).
  • Cabarrocas X, Salva M. Almotriptan has no pharmacokineticipharmacodynamic interaction with ethanol. Cephalalgia 22(7), 605 (2002).
  • Cabarrocas X, Macher J-P Lack of pharmacokinetic interaction between almotriptan and oral contraceptives: a double-blind, placebo-controlled, crossover study in healthy female volunteers. Cephalalgia 23(7), 716 (2003).
  • Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgla 8\(Suppl. 7), 1–92 (1988).
  • Pilgrim AJ. Methodology of clinical trials of sumatriptan in migraine and cluster headache. Eur Neural. 31, 295–299 (1991).
  • Pascual J. Almotriptan: a novel 5-HT1B/ID agonist for the symptomatic relief of migraine. Exp. Rev Neurotherapeutics1(1), 20–7 (2001).
  • Boyce M, Dunn K, Warrington S. Haemodynamic and electrocardiographic effects of almotriptan in healthy volunteers. Catrliovasc. Pharmacol 37, 280–289 (2001).
  • DahlOf C, Tfelt-Hansen P, Massiou H, Fazekas A. Dose-finding, placebo-controlled study of oral almotriptan in the acute treatment of migraine. Neurology57, 1811–1817 (2001).
  • ••The definitive dose-finding studywith almotriptan.
  • Pascual J, Falk RM, Piessens F et al. Consistent efficacy and tolerability of almotriptan in the acute treatment of multiple migraine attacks: results of a large, randomised, double-blind, placebo-controlled study. Cephalalgia 20, 588–596 (2000).
  • ••A key Phase III study with almotriptan.
  • Dowson AJ, Massiou H, Lainez JM, Cabarrocas X. Almotriptan is an effective and well-tolerated treatment for migraine pain: results of a randomized, double-blind, placebo-controlled clinical trial. Cephalalgia 22, 453–461 (2002). A key Phase In study with almotriptan.
  • Spierings EL, Gomez-Mancilla B, Grosz DE, Rowland CR, Whaley FS, Jirgens KJ. Oral almotriptan versus oral sumatriptan in the abortive treatment of migraine: a double-blind, randomised, parallel-group, optimum-dose comparison. Arch. Neural. 58, 944–950 (2001).
  • ••A key Phase III study with almotriptan.
  • Mathew N. A long-term open-label study of oral almotriptan 12.5 mg for the treatment of acute migraine attacks. Headache 42, 32–40 (2002).
  • Pascual J, Falk RM, Docekal R et al. Tolerability and efficacy of almotriptan in the long-term treatment of migraine. Eur Neural. 45, 206–213 (2001).
  • Pascual J, Lainez JM, Leira R et al Almotriptan in the treatment of migraine attacks in clinical practice: results of the TEA 2000 observational study. Neurologla 18(1), 7–17 (2003).
  • Pascual J. Almotriptan in the treatment of migraine attacks in clinical practice: results of the TEA 2001 observational study. Headache 43, 525 (2002).
  • Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT1B/ID agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 22, 633–658 (2003).
  • Dahl& CG, Dodick D, Dowson AJ, Pascual J. How does almotriptan compare with other triptans? A review of data from placebo-controlled clinical trials. Headache 42, 99–113 (2002).
  • Dodick DW. Almotriptan increases sustained pain-free outcomes in acute migraine: results from three controlled clinical trials. Headache 42, 21–27 (2002).
  • Mathew NT Use of rescue medication in trials of almotriptan versus placebo in the treatment of acute migraine. Clin. Ther 24, 520–529 (2002).
  • Cady R. Almotriptan reduces the incidence of migraine-associated symptoms: a pooled analysis. Headache 42 (Suppl. 1), 26–31 (2002).
  • Cady RK, Lipton RB, Hall C et al Treatment of mild headache in disabled migraine sufferers: results of the Spectrum study. Headache 40, 792–797 (2000).
  • •Landmark study that has demonstrated that triptans are most effective when used early in the migraine attack, when the headache is mild in intensity
  • Pascual J, Cabarrocas X. Within-patient early versus delayed treatment of migraine attacks with almotriptan: the sooner the better. Headache 42,28–31 (2002).
  • Dowson AJ, Massiou H, Lanez JM, Cabarrocas X. Almotriptan improves response rates when treatment is within 1 h of migraine onset. Headache (2004) (In Press).
  • Dodick DW. Oral almotriptan in the treatment of migraine: safety and tolerability. Headache41,449–455 (2001).
  • Colman SS, Brod MI, Krishnamurthy A, Rowland CR, Jirgens KJ, Gomez-Mancilla B. Treatment satisfaction, functional status and health-related quality of life of migraine patients treated with almotriptan or sumatriptan. Gun. Ther. 23,127–145 (2001).
  • Mayo KW, Osterhaus JT. Health outcomes evaluations: estimating the impact of almotriptan in managed care settings. Am.J Manag. Care 8, S85—S93 (2002) .
  • Wang JT, Barr CE, Goldfarb SD. Impact of chest pain on cost of migraine treatment with almotriptan and sumatriptan. Headache 42 (Suppl. 1), 38–43 (2002) .
  • Williams P, Reeder CE. Cost-effectiveness of almotriptan and rizatriptan in the treatment of acute migraine. Gun. Ther. 25, 2903–2919 (2003).

Website

  • Silberstein SD, for the US Headache Consortium. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. www.neurology.org/cgi/reprint/55/6/754.pdf (Accessed April 2004)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.